throbber
(19) United States
`(12) Patent Application Publication (10) Pub. No.: US 2014/0219919 A1
`EDWARDS et al.
`(43) Pub. Date:
`Aug. 7, 2014
`
`US 20140219919A1
`
`(54) IL-11 RBINDING PROTEINS AND USES
`THEREOF
`
`(71) Applicant: CSL Limited, Parkville (AU)
`(72) Inventors: Kirsten EDWARDS, Parkville (AU):
`Matthew HARDY, Parkville (AU):
`Veronika RAYZMAN, Parkville (AU):
`Michael WILSON, Parkville (AU)
`
`(73) Assignee: CSL Limited, Parkville (AU)
`
`(21) Appl. No.: 14/174,009
`
`(22) Filed:
`
`Feb. 6, 2014
`
`Related U.S. Application Data
`(60) Provisional application No. 61/764,756, filed on Feb.
`14, 2013.
`
`(30)
`
`Foreign Application Priority Data
`
`Feb. 7, 2013 (AU) ................................ 2O1390O389
`Publication Classification
`
`(2006.01)
`(2006.01)
`(2006.01)
`
`(51) Int. Cl.
`C07K 6/28
`GOIN33/569
`A614.9/00
`52) U.S. C.
`(52) CPC ............. C07K 16/2866 (2013.01); A61K 49/00
`(2013.01); G0IN33/56966 (2013.01)
`USPC ... 424/9.1; 530/389.1:530/387.9; 530/387.3;
`530/391.1:536/23.53; 435/320.1; 435/252.33;
`424/172.1; 435/7.21: 435/254.2:435/334
`ABSTRACT
`(57)
`The present disclosure provides proteins comprising antigen
`binding sites of antibodies that bind to interleukin-11 (IL-11)
`receptor alpha (IL-11 RO) and uses thereof, e.g., in therapy.
`
`Lassen - Exhibit 1008, p. 1
`
`

`

`Patent Application Publication
`
`Aug. 7, 2014 Sheet 1 of 8
`
`US 2014/0219919 A1
`
`832 L3.2 DNLSPT
`TS~49
`ESQAPE
`TS“51
`ESQWPF
`
`ETQTPA
`TS*55
`TSHS7
`ETQMEL
`TS~53
`ETQQPF
`TS’SB
`DTQQPN
`T$“64
`ESQWPQ
`Com§nmw ETngF
`
`8E2 Ll ENNELN
`TS“3Q3
`VDYWVE
`TS~305
`VGIYVE
`TS*306
`VDKYVE
`T8m307
`VSMYVZ
`TS~310
`VAM?IE
`TS"311
`VSQYIE
`TS—312
`IGQYVE
`TS‘313
`VSGYUE
`TS~322
`VHHYME
`Consensus VSXYVE
`
`
`
`832 23.1 QQYDNL
`
`QQAEDQ
`TS‘E
`TE—é
`QQHEFQ
`TS—6
`EQFESQ
`TSfl7
`QQHENQ
`TS*9
`QQAEEQ
`TS“13
`QQNETQ
`Tg*lé
`QQEUNQ
`T3‘l7
`SQFESQ
`TS—QO
`QQNESQ
`TS~2 l
`QQSESQ
`TS‘ZZ
`QQFETQ
`TE? ~21 9
`QQSEEQ
`TS—32
`TQWETQ
`Cnnsenans
`QQKESQ
`
`Figure 1
`
`Lassen — Exhibit 1008, p. 2
`
`Lassen - Exhibit 1008, p. 2
`
`

`

`Patent Application Publication
`
`Aug. 7, 2014 Sheet 2 of 8
`
`US 2014/0219919 A1
`
`SWYSMT
`AWWS IA
`GWWSVT
`ERNST”
`9‘?ng 1‘1‘
`AWFS‘VM
`WRWS‘W’
`WRWSTT
`
`
`
`8E2 H1
`TS — 6 6
`TS‘SE}
`TS*71
`TS "75
`TS'~79
`TSAEZ
`TS~88
`
`WPWSI”
`TS ----- S 9
`EWYSJI.‘L1
`TSMQQ
`GWWSLT
`TS- 91
`SWWSIT
`T3” 92
`Consensus WW5 ET
`
`83.19. H3 . 3. GPGWGS
`‘“
`"
`
`
`
`a
`F?
`
`Consangus
`PEDWGX
`
`8E2 H2 VPSGGH
`TS # 9‘7
`VPWADY
`TSWIUl
`VPWGDL
`TS~103
`VPYC—QDL
`TS-“loli
`VPWGTI
`TS--l‘37
`VPWSDF
`TS~108
`VPWGTL
`TEX-“115
`VPi’iGDL
`
`Congensug VPWGDL
`
`Figure 2
`
`8E2 HS .2 WGSFDL
`T S —2 l 3
`WGQ FAV
`WGSFWF
`TEE—214
`
`WGSFWQ
`WIS—215
`TEE—218
`WGS ENE
`T’s—221
`WGSFWY
`TS~222
`WGTFAY
`TVS—224
`WGSFW’I‘
`
`Consensus WGSFWY
`
`Lassen — Exhibit 1008, p. 3
`
`Lassen - Exhibit 1008, p. 3
`
`

`

`Patent Application Publication
`
`Aug. 7, 2014 Sheet 3 of8
`
`US 2014/0219919 A1
`
`CDRZ
`r————————~
`DASNLQT
`
`
`
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQT
`DASNLQI
`DASNLQT
`DASNLQT
`DASNLQT
`
`DASNLQT
`
`8E2
`
`DIQMTQSPSSLSASVGDRVTITC
`
`INNYLN WYQQKPGKAPKLLIY
`
`CDRl
`
`DIQMTQSPSSLSASVGDRVTITC
`VDYWVE WYQQKPGKAPKLLIY
`VGIYVE WYQQKPGKAPKLLIY
`DIQMTQSPSSLSASVGDRVTITC
`DIQMTQSFSSLSASVGDRVTITC
`VDKYVE WYQQKPGKAPKLLIY
`VSMYVE WYQQKPGKAPKLLIY
`DIQMTQSPSSLSASVGDRVTITC
`DIQMTQSPSSLSASVGDRVTITC
`VAMYIE WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTITC
`VSQYIE WYQQKPGKAPKLLTY
`
`DIQMTQSPSSLSASVGDRVTITC
`IGQYVE WYQQKPGKAPKLLIY
`DIQMTQSPSSLSASVGDRVTITC
`VSGYVE WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTITC
`VHHYME WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTITC
`INNYLN WYQQKPGKAPKLLIY
`INNYLN WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTITC
`DIQMTQSPSSLSASVGDRVTITC
`INNYLN WYQQKPGKAPKLLIY
`
`DIQMIQSFSSLSASVGDRVTITC
`INNYLN WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTITC
`INNYLN WYQQKPGKAPKLLIY
`DIQMTQSPSSLSASVGDRVTITC
`INNYLN WYQQKPGKAFKLLIY
`
`DIQMTQSPSSLSASVGDRVTIIC
`INNYLN WYQQKPGKAPKLLIY
`DIQMTQSPSSLSASVGDRVTIIC
`INNYLN WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTITC
`INNYLN WYQQKPGKAPKLLIY
`
`INNYLN WYQQKPGKAPKLLIY
`DIQMTQSPSSLSASVGDRVTITC
`
`DIQMTQSPSSLSASVGDRVTITC
`INNYLN WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTIIC
`INNYLN WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTIIC
`INNYLN WYQQKPGKAPKLLIY
`DIQMTQSPSSLSASVGDRVTITC
`INNYLN WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVIITC
`INNYLN WYQQKPGKAPKLLIY
`
`INNYLN WYQQKPGKAPKLLIY
`DIQMTQSPSSLSASVGDRVTITC
`DIQMTQSPSSLSASVGDRVTITC
`INNYLN WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTIIC
`INNYLN WYQQKPGKAPKLLIY
`DIQMTQSPSSLSASVGDRVTITC
`INNYLN WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTITC
`INNYLN WYQQKPGKAPKLLIY
`
`DIQMTQSPSSLSASVGDRVTITC
` XXXXXX WYQQKPGKAPKLLIY
`INNYLN
`VDYWVE
`GI
`I
`SK M
`AM
`HQ
`
`GH
`
`Figure 3A
`
`TS~303
`18—305
`TS~306
`TS~307
`TS—3lO
`TS—3ll
`TS‘312
`TSv313
`TS~322
`TS—Z
`TS—4
`TS—S
`TS—7
`TS—9
`TSvl3
`TS—14
`TS—l7
`TSv2O
`TS-Zl
`TS—ZZ
`TS~29
`TS—32
`IS~49
`TS~51
`TS~55
`TSw57
`TSw58
`TS—63
`TSv64
`Consensus
`
`Lassen — Exhibit 1008, p. 4
`
`Lassen - Exhibit 1008, p. 4
`
`

`

`Patent Application Publication
`
`Aug. 7, 2014 Sheet 4 of 8
`
`US 2014/0219919 A1
`
`CDR3
`
`8E2
`15—303
`TS~305
`TS«306
`15—307
`TS~310
`15-311
`TS~312
`IS 313
`Ts~322
`IS—z
`13—4
`IS‘S
`TSv7
`ISuB
`13-13
`15—14
`13-17
`TS-ZC
`15—21
`15—22
`TS—29
`T8732
`TS 49
`TS~Sl
`TSvSS
`TS—57
`TS~56
`1S~53
`TS—64
`
`Consensus
`
`SVPSRESGSGSETDETET:SSLQPEDIAIYYC QQYDNL SPT FGPGTKVDIK
`GVPSRFSGSGSGIDFTFTISSLQPEDIATYYC QQYDNL SPT FGPGTKVDIK
`GVPSRESGSGSGTDEIET1SSLQEEDIATYYC QQYDNL SPT FGPGTKVDIK
`GVPSRFSGSGSGIDFTFTISSLQPEDIAIYYC QQYDNL SPT FGPGTKVDIK
`GVPSRFSGSGSGTDFIFTISSLQPEDIATYYC QQYDNL SPT FGPGTKVDIK
`GV?SRFSGSGSGTDFTPTISSLQPEDIAIYYC QQYDNL SPT FGPGTKVDIK
`
`ATYYC QQYDNL SPT FGPGTKVDIK
`GVPSRFSGSGSGIDFTFIISSLQPE
`GVPSRFSGSGSGTDFTFTISSLQPE
`IYYC QQYDNL SPT FGPGTKVDIK
`GVPSRFSGSGSGTDFTFTISSLQPE _ TYYC QQYDNL SPT FGPGTKVDIK
`
`GVPSRFSGSGSGTDFTFTISSLQEEDIATYYC QQYDNL SPT EGPGTKVDIK
`GVPSRFSGSGSGIDFTFTISSLQPEDIAIYYC QQAEDQ SPT EGPGLKVDIK
`GVPSRFSGSGSGTDFTFTISSLDPEDiATYYC QQHBFQ SET FGPGTKVDIK
`GVPSRESGSGSGIDETEIISSLQPEDIAIXYC EQFESQ SPT VGPGTKVDIK
`GVFSRFSGSGbGIDFTETlSSLQPEDTATYYC QQHENQ SPT EGPGTKVDIK
`GVPSRESGSG dIDFTFTTSSLQPEDIATYYC QQAEEQ SPT FGPGTKVDIK
`GVPSRESGSGSGTDFTFTTSSLQPEDIATYYC QQNETQ SPT PGPGTKVDIK
`GVPSRFSGSGSGTDFTFTISSLQPEDIATYYC QQHDNQ SPT FGPGTKVDIK
`GVPSRFSGSGSGTDFTFTISSLQPEDIATYYC SQFESQ SPT FGPGIKVDIK
`GVPSRFSGSGSGTDFIFTISSLQPEDIATYYC QQNESQ SET FGPGTKVDIK
`GVPSRFSGSGSGTDFTFTISSLQPEDIATYYC QQSESQ SPT FGPGTKVDIK
`GVPSRFSGSGSGTDFTFTISSLQPEDIATYYC QQEEIQ SET FGPGTKVDIK
`GVPSRFSGSGSGTDFTFTISSLQPEDIATYYC QQSEEQ SPT FGPGIKVDIK
`GVPSRFSGSGSGTDFTFTISSLQPEDIATYYC TQWElQ SET FGPGIKVDIK
`GVPSRFSGSGSGTDFTFTISELQPEDIATYYC QQYEEQ APE FGPGTKVDIK
`GVPSRFSGSGSGTDFTFTISSLQPEDIATYYC QQYESQ WPF FGFGIKVDIK
`GVPSRFSGSGSGTDFIFTISSLQPEDIATYYC QQYErQ TEA FGPGTKVDIK
`GVPSRFSGSGSGTDFIFTISSLQEEDIAIYYC OOYETQ MPL FGPGIKVDLK
`GVPSRFSGSGSGTDFTFTTSSLQPEDIATXYC QQYEIQ QEE FGPGTKVDlK
`GVPSRFSGSGSGTDFTFTISELOPEDIAIYYC QQYDTQ DEN EGPGIKVDLK
`GVPSRFSGSGSGTDFTFIISSLQPEDlATYYC QQYESQ WPQ EGPGTKVDIK
`
`GVESEESSSGSGTDEiETiSSLQPEDTATYYC XQXXXX xpx FGPGTKVDIK
`.Q YDNL s T
`iE AEDQ A E
`E S H F
`w F
`ii F S
`I A
`g
`N E
`M L
`a
`s T
`Q N
`a
`w
`c
`
`
`
`
`
`5
`SEQ ID NO:
`6
`SEQ ID NO:
`7
`SEQ I
`NO:
`8
`SEQ ID NO:
`9
`SEQ ID NO:
`10
`SEQ ID NO:
`11
`SEQ ID NO:
`12
`SEQ ID NO:
`13
`SEQ 1D NO:
`SEQ ID NO: 14
`SEQ ID NO:
`15
`SEQ TD NO:
`16
`SEQ ID NO:
`17
`SEQ ID NO:
`is
`SEQ ID NO:
`19
`SEQ ID NO: 20
`SEQ ID NO: 21
`SEQ ID NO:
`2
`SEQ ID NO: 23
`SEQ ID NO: 24
`SEQ ID NO: 25
`SEQ ID NO: 26
`SEQ ID NO:
`SEQ ID NO:
`SEQ ID NO:
`SEQ ID NO:
`SEQ ID No:
`SEQ in No:
`SEQ ID NO:
`SEQ ID NO:
`
`
`
`SEQ ID NO:
`
`
`35
`
`Figure 3A Continued
`
`Lassen — Exhibit 1008, p. 5
`
`Lassen - Exhibit 1008, p. 5
`
`

`

`Patent Application Publication
`
`Aug. 7, 2014 Sheet 5 of 8
`
`US 2014/0219919 A1
`
`CDRI
`
`CDRZ
`
`
`DLQMTQSPSSLSASVQDRVTITC QASQD Ii
`LN WYQQKPGKAPKLLTY LASNLQT
`
`DIQMTQSPSSLSASVGDRVTITC QASQD VDKYVE WYQQKPGKAFKLLIY bASNLQT
`DIQMTQSPSSLSASVCDRVTITC QASQD INNYLN WYQQKPGKAPKLLIY DASNLQT
`DIQMTQSPSSLSASVGDRVTTTC QASQ;
`IENYLN WYQQKPGKRPKLLIY DASNLQT
`DIQMTQSPSSLSASVCDRVTTTC QASEC TNNYLN WXQQKFSKAPKLLIY DASNLQT
`DIQMTQSPSSLSASVGDRVTITC QASQD INNYLN WXQQKFGKAPKLLLY DASNLOT
`DTQMTQSPSSLSASVGDEVTITC QASQU LNNYLN WYQQKPGKAPKLLIY DASNLOT
`DIQMIQSPSSLSAhVGDRVTITC
`XXXYXX WYQQKPGKAFKLLIY ASNLQT
`IDK LN
`VNN V3
`
`
`
`
`
`SEQ
`
`ID NO:
`
`CDR?
`
`FGPGTKVDIK
`FGPGTKVDIK
`FGPGTKVDIK
`FGPGTKVDIK
`FGPGTKVDIK
`FGPGTKVDIK
`FGVGTKVDIK
`FGDGTKVUTK
`
`SEQ
`SEO
`SEQ
`
`SEQ
`SEQ
`SEQ
`
`
`
`
`
`GVPSRFSGSSSGTDFTFTTSSLQPEDIATYYC
`
`GVPSRFSSSGSGTDFTFTTSSLQ EDIATYYC QQYDNL
`
`
`
`.IATY" QQAEDQ
`GVPSRFSGSGSGTDFTFTIS LQ
`
`GVVSRFSa°fl
`C QQHEFC
`TDFTFTluaLQPLDiATY:
`
`
`FTFTLSSLQYEDIATYYC
`QOHENC
`
`‘SSSGSGTUFTPTISSLOPEDIATYVC
`
`QQHDNQ
`
`
`GYPSRFSGSGSGTDFTFTISSLQPEDIAT
`{C QQYESQ
`QQXXXXYDNI‘
`AEDQ w F
`H F
`
`N5
`
`
`
`Figure SB
`
`Lassen — Exhibit 1008, p. 6
`
`BEZ
`TS~306
`TS-Z
`TS-4
`TS—7
`TS—ld
`TS-El
`
`Ccnse‘)
`
`8E2
`
`Consensus
`
`Lassen - Exhibit 1008, p. 6
`
`

`

`Patent Application Publication
`
`Aug. 7, 2014 Sheet 6 of 8
`
`US 2014/0219919 A1
`
`COR;
`
`CDRZ
`
`8E2
`
`T6-66
`T5769
`TS~71
`TS~76
`TS~79
`TS—SZ
`TS'SB
`TS~89
`TF~91
`TS—92
`TS—97
`
`
`
`Consensus
`
`
`
`EVQLLESGGG VQFGGSLRLSCAASGFTP
`
`EVQLLESGGGLVQPGGSLRLSCAASGFIF
`EVQLLESGGGLVQPGGSLR,QSAASGFTF
`
`EVQLLESGGGLVQPGGSLRLSuAASGFTF
`EVQLLESGGGLVQPGGSLRLSCAASGFTF
`EVQLLESGGGLVQPGGSLRLSCAASGFTF
`EVQLLESGGGLVOPGGSLRLSCAASGFTF
`EVQLLESGGGLVQPGGSLRLSCAASGFTF
`E
`LLESGGGLVQPGGSLRLSCAASGFTF
`
`EVQLLESGGGLVQPGGSLRLSCAASGFTF
`EVQLLESGGGLVOPGGSLRLSCAASGFTF
`EVQLLESGGGLVQPGGSLRLSCAASGFTF
`EVQLLESGGGLVQPGGSLRLSCAASGFTF
`QLLESGGGLVQPGGSLRLSCRASGFTF
`QLLESGGGLVQPGGSLRLSCAASGFTF
`QLLESGGGLVQPGGSLRLSCAASGFTF
`QLLESGGGLVQPGGSLELSCAASGET?
`VQLLESGGGLVQPGGSLRLSCAASGFTE
`
`QLLESGGGLVQPGGSLRLSCAASGFTF
`, QLLESGGGLVQPGGSLRLSCAASGFTE
`
`EVQLLESGGGLVQPGGSLRLSCAASGFIF
`
`EVQLLESGGGLVQPGGSLFLSCAASGFTF
`
`EVQLLESGGGLVQPGG
`RLSCAASUBIE
`EVQLLESGGGLVOPGGSLRLSCAASGFIF
`EVQLLESGGGLVQPGGSLRLSCAASGFTF
`EVOLLESGGGLVQPGGSLRLSCAASGF
`
`
`EVQLLESGGGLVQPGGSLRLSCAASGFI:
`EVQLLESGGGLVQPGGSLRLSCAASGFTF
`
`EVQLLESGGGLVQPGGSLRLSCAASGAIF
`EVQLLESGGGLVQPGGSLRLSCAASGFT?
`EVQLLESGGGLVQPGGSLRLSCAASGFIF
`EVQLLESGGGLVQPGGSLRLSCAAS1F
`
`
`EVQLLESGGGLVQPGGSLRLSCAASG
`EVQLLESGCCLVQPGGSLRLSCAASGFIF
`SVOLLESGGGLVQPGGSLRLSCAASGFT?
`
`m
`
`Lamar/2mmmmmmmmmmmmmmmmmmmmmiz"
`
`SaWmK
`
`
`
`
`
`Figure 3C
`
`Lassen — Exhibit 1008, p. 7
`
`
`
`IOYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`IQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TOYADSVKG
`TQYADSVKG
`IQYADSVVG
`TQYADSVI
`
`TQYADSVKG
`TQYADSVKG
`TQYADSVKC
`TQYADSVKG
`q
`TQYADS
`
`TQYADSVWG
`TQYADS
`
` a
`
`TQVADSV'
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`
`TQYADSVKG
`
`VPSGCH
`VPSGGH
`VPSGGH
`VPSGGH
`VPSG .
`
`VPSGGH
`VPSGGH
`VPSGCH
`VPSGGH
`VPSGGH
`VPSGGH
`VFWADY
`VPWGDL
`VPYGDL
`VPWGTI
`VPNGDE
`VPWGTL
`VPHGDL
`VPSGGH
`VPSGGE
`PSGGH
`VPSGGE
`VPSGGH
`VPSGGH
`VPSGGE
`VPSGCH
`VPSGGH
`VPSGGE
`VPSGGH
`VPSGGE
`VPSGGE
`VPSGGH
`VPSCGE
`VPSGGE
`VPXXXX
`SGGE
`WADY
`Y TL
`H
`
`TF
`
`HhHHHHHHHH
`
`H,;
`
`u
`
` H
`><HHHHHHHHHHHHkuHHHHHHH
`
`WVRQA?GKGLEWVS
`
`WYSMT WVRQAPGKGLEWVS
`
`NWSIA
`WVRQAPGKGLEWVS
`WWSVT
`
`WVRQAPGKGLEWVS
`MSTT
`WVRQAPGKGLEWVS
`
`,WSIT
`WVRQAPGKGLEWVS
`
`IFSVT
`WVRQAPGKGLEWVS
`
`WSVT
`WVRQAPGKGLEWVS
`RWS"T
`WVPQAFGKGLEWVS
`
`RWSTT
`WVRQRPGKGLEWVS
`VWSLT
`WVRQAPGKGLEWVS
`
`IWSIT
`WVRQAPGKGLEWVS
`VYSMT
`WVRQAPGKGLEWVS
`
`IYSMT
`WVRQAPGKGLEWVS
`WYSMT
`WVRQAPGKGLEWVS
`'JYSMT
`WVRQAPGKGLEWVS
`
`JYSMT
`WVEQAPGKGLEWVS
`NYSMT
`WVRQAPGKGLEWVS
`WYSMT
`WVEQAPGKGLEWVS
`
`IYSMT
`WVRQAPGKGLEWVS
`WYSMT
`WVRQAPGKGLEWVS
`WISMT
`WVRQAPGKGLEWVS
`
`WYSMT
`WVRQAPGKGLEWVS
`VYSMT
`WVROAPGKGLEWVS
`WYSMT
`WVRQAPGKGLEWVS
`JYSMT
`WVRQAPCKCLEWVS
`WYSMT
`WVRQAPGKGLEWVS
`JYSMT
`WVRQAPGKGLEWVS
`WYSMT
`WVRQAPGKGLEWVS
`WYSMT
`WVEQAPGKGLEWVS
`WYSMT
`
`WVRQAPGKGLEWV
`XSMT
`WVRQAEGKGLEWVS
`WYSMT
`
`WVRQAPGKGLEWV‘
`YSMT
`WVRQAPGKGLEMVS
`WYSMT
`hVRQAPGKGLEWVS
`XSXX
`WY MT
`
`Lassen - Exhibit 1008, p. 7
`
`

`

`Patent Application Publication
`
`Aug. 7, 2014 Sheet 7 of8
`
`US 2014/0219919 A1
`
`CD83
`NO'
`NO:
`NO:
`NO
`NC
`NO:
`NO:
`NO:
`NO:
`NO:
`NO:
`NO:
`NO:
`NO:
`NO:
`NO:
`NC:
`NC:
`NO:
`NO:
`NC:
`NC:
`
`
`
`lD
`TD
`ID
`ID
`LD
`TD
`ID
`ID
`ID
`£D
`TD
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`ID
`LU
`ID
`ID
`ID
`
`
`ID
`
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`SEQ
`A q
`
`mmmmmmmmmmmmmm'
`
`~31{umm‘9:LumL!)mD1{A1LL-mD}:
`
`p)ao
`
`00000000000000
`
`[1)Lu2mmm m 0
`wb: c
`m m @
`
`Figure 3C Continued
`
`Lassen — Exhibit 1008, p. 8
`
`VLNHE
`
` 29
`
`l33
`
`T87134
`TS-l35
`TS—136
`‘
`l40
`1“ 143
`
`TS*151
`TS~156
`TE~213
`T372l4
`TSr2WS
`TS—218
`TS—ZZl
`TS~222
`TS~224
`Consensus
`
`EFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
`RFTTSRDNSKNTLYLQMNSLRBVDVA”YYCAK
`RFTISRDNSKNTLYLQMNSLRP
`YYCRK
`
`RFIISRDNSKNTIYLQMNSLRAED AVYYCAK
`RPTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
`RFTLSRDNSKNILYLQMNSLRAED AVYYCAX
`RFTT5RDUSKNTLYLQMNSLRAEDTAVYYCAK
`RF:ISRDNSKNTLYLQMNELEAEDTAVXECAK
`EFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
`KFTISRDNS NTLYLQMNSLRAEDTAVYYCAK
`
`RFTISRDN
`NSLRAEDTAVYYCAK
`RFTISRDN”iNTLYLQMNSLRAEDIAVYYCAK
`RFTISRDNS NTLYIQMNSLRAEDTAVYYCAK
`RFTISRDNSANTLYLQMNSLRAEDIAVYYCAK
`RFTISRDNSKNTLYLOMNSLRAEDIAVYYCAK
`RFTTSRDNSiNTLYLQMNSLRAEDTAVYYCAK
`REIISRDNSKNTLYDQMNGLBEBDIAVXYCAK
`RETISRDNSKNTLYLCMNS RAEDTRVYYCRV
`RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
`
`R TISRDNSKNTLYLCMNSLRAEDTAVYYCAK
`R:TlERDNSKNTLYLQMNSLRAEDTAVYYCAK
`
`RETISRDNSKNTLYLQMNS RAEDlAVYYCAK
`RETISRDNSKNTLYLQMNSLRAEDTRVYYC3?
`RFTISRDNSKNTLYLQMNSLRAEDTAVYYF
`KFTIERDNSKNTLYLOVNSLRAEDTAVYYCA
`
`3 TISRDNSKNTLYI
`SLRAEDTAVXYCAK
`
`R TISRDNSKNTLYLQMNSLRAEDTAVYVCAK
`
`R TISRDNSKNT'YLQMNSLRAEDTAVY
`RFTISRDNSKNT ILQMNSLRAEDTAVY’
`.
`
`
`RFTl5RDNSKNTLYLQMNSLRABDTAVYYCAS
`
`RFTTSRRNSKNTLYLQMNSLRAEDTAVYYCAK
`RFTISRDNSKNTuYLQMNSLRAEDTAVYYVAK
`RFTISRDNSKNT ILQMNSLRREDTAVYYF
`.
`
`
`RFTISRDNSKNTLYLQMNSLRAEDIAVYYCAK
`
`RFTISHDNSKNTLYLQMNSLRAEDTAVYYCAK
`
`acr'wzm
`
`_ WGREILVTVSS
`
`GPS
`WGSFDL
`WGRGTLVTVSS
`GEE
`
`WG FDL
`WGEGTLVTVSS
`GPG
`WGSFDL
`WGFGILVIVSS
`CPS
`WGSFDL
`WGRGTLVTVSS
`GPG
`WGRGTLVTVSS
`WGSFDL
`GPG
`WGSFDL
`WGRGTLVTVSS
`GPG G:G
`WGSFDL
`WGRGTLVTVSS
`WGSFDL
`WGRGILVTVSS
`GPG
`WGSFDL
`WGRGTLVTVSS
`GPG
`WGRGILVTVSS
`WGSFDL
`GPG
`WGSFDL
`WGRGTLVTVSS
`GFG
`WGSFDL
`WGRGTLVDVSS
`WGSFDL
`CPS
`WGHGTLV
`SS
`
`CFC
`wcsrnL
`WGRGTLVA SS
`WGRGTLVTVSS
`GPG
`WGSFDL
`GPG
`WESFDL
`WGRGTLVEVSS
`GPG
`WGSFDL
`WGRGTLV”VSS
`EED
`WGMFEL
`WGQGT’
`
`PVD
`WGPFEL
`
`WGRGTI‘
`‘.
`
`WG FDL
`FED
`WGRGTLVIV
`PLD
`WGLFDL
`WGRGTL
`FLU
`WGRFrL
`
`WGRGTI
`PND
`WGRGTL
`wc FLL
`PHD
`WGRGTLV
`WULFDL
`PHD
`WGRFDL
`WGRGTL
`WGRFDL
`
`FED
`WGRGTL‘
`GFG
`WGRGTL
`WGQFAV
`GFG
`wcstr
`WGRGT'LV’r
`WGRGTLVTV
`GFG
`WGSFWQ
`
`GPG
`WGSFWE
`WGRGTL‘
`GPG
`WGSFWY
`WGRGTLV;
`
`WGRGTL
`GFG
`WGTEAZ
`WGSFMT
`GPG
`WGRGTLVLVSS
`
`WGXFXX
`XXX
`WGRGTIVTVSS
`GFG
`DL
`AV
`PED
`WF
`
`
`
`QEYT
`
`Lassen - Exhibit 1008, p. 8
`
`

`

`Patent Application Publication
`
`Aug. 7, 2014 Sheet 8 of 8
`
`US 2014/0219919 A1
`
`2 I
`
`QYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADSVKG
`TQYADQVVG
`TQYADSVKG
`
`’1,
`
`CDR
`VPSGGH
`VFWGDL
`VPWGTL
`VPSGGH
`VPSGGH
`VPXGXX
`5 GH
`W DL
`
`WVRQAPGKGLEWVS
`WVRQATGKGLEWVS
`WVRQAPGKGLEWVS
`WVRQAPGKGLEWVS
`WVRQAPGKGLEWVS
`WVRQAPGKGLEWVS
`
`
`
`CDRI
`NYSMT
`WYSMT
`IIYSMT
`WYSMT
`JYSMI
`flYSMT
`
`S mwmm
`
`EVQLLESGGGLVQPGGSLRLSCAASGFTF
`
`EVQLLESGGGLVQPGGSLRLSCAASG
`EVQLLESGGGLVQPGGSLRLSCAASGA
` m
`BVQLLESGGGIVQPGGSLRLSCAASGF
`EVQLLESGGGLVQPGGSLRLSCABSG.M
`EVQLLESCCCLVQPGGSLRLSCAASGETF
`
`832
`TS—lDl
`TS—lOB
`:37134
`TS~136
`Consensus
`
`
`GPG
`GPG
`GPG
`PED
`PLD
`XXX
`GPG
`PED
`L
`
`
`
`ID NO: 37
`10 NO:
`49
`ID NO:
`33
`ID NO:
`5
`ID NO:
`5
`ID NO:
`72
`
`Lassen — Exhibit 1008, p. 9
`
`
`WGSFDL WGRGTLVTVSS
`
`
`WGDGTTVTV
`WGSFDL
`WGSFDI
`WG:
`LVTVSS
`
`
`WGLFDL
`WGRGTLVTVSS
`WGRFDL
`WGRGTLVTVSS
`
`WCXFD;
`WGRGTLVTVSS
`
`
`SLR
`
`IfigurEBD
`
`1a
`TS
`IS
`
`IS
`
`Consensus
`
`RFIISRDNSKNELYLQMNSLRAEDTAVYYCAK
`RETISRDNSKNT
`LYLQMNSLRAEDTAVYYCAK
`RFTISRDNSKN”LYLQMNSLRAEDEAVYYCAK
`
`AVYYCAK
`RFTISRDNSKNTLYLQMNSDRAL
`DTAVYYCAK
`RVTiSHDNSKNTLYLQMNSLR
`
`RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK
`
`
`
`Lassen - Exhibit 1008, p. 9
`
`

`

`US 2014/02199 19 A1
`
`Aug. 7, 2014
`
`IL-11 RBINDING PROTEINS AND USES
`THEREOF
`
`RELATED APPLICATION DATA
`0001. The present application claims priority from Aus
`tralian Patent Application No. 2013900389 entitled “IL-11R
`binding proteins and uses thereof filed on 7 Feb. 2013 and
`from U.S. Patent Application No. 61/764,756 entitled “IL
`11 Rbinding proteins and uses thereof filed on 14 Feb. 2013.
`The entire contents of those applications are hereby incorpo
`rated by reference.
`
`SEQUENCE LISTING
`0002 The Sequence Listing in the ASCII text file, named
`as P29799 SequenceListingProvisional.txt of 164 KB, cre
`ated on Feb. 14, 2013, and submitted to the United States
`Patent and Trademark Office via EFS-Web, is incorporated
`herein by reference.
`
`FIELD
`0003. The present disclosure relates to proteins compris
`ing antigen binding sites of antibodies that bind to interleu
`kin-11 (IL-11) receptor alpha (IL-11 RC.) and uses thereof,
`e.g., in therapy.
`
`BACKGROUND
`0004 IL-11 is a member of the IL-6 cytokine family which
`also comprises IL-27, IL-31, leukemia inhibitory factor
`(LIF), oncostatin M (OSM) and ciliary neurotrophic factor
`(CNTF) amongst others. IL-6 family cytokines induce signal
`transduction via a common signal-transducing receptor
`B-subunit, gp130 and a specific receptor C-Subunit. In the
`case of IL-11, binding of this cytokine to its specific receptor
`C.-subunit, IL-11 RC, induces gp130 homodimerization.
`Dimerization of gp130 activates the JAK/STAT signaling
`pathway and leads to the activation of signal transducer and
`activator of transcription (STAT) 3 (STAT3) and to a lesser
`extent, STAT1.
`0005 IL-11 signaling is known to play a role in hemato
`poiesis, immune response, inflammation, adipogenesis,
`osteoclastogenesis, neurogenesis, megakaryocyte maturation
`and platelet production. IL-11 is used clinically or is in devel
`opment for treating a variety of conditions, e.g., chemo
`therapy-induced thrombocytopenia, and various inflamma
`tory disorders including arthritis, inflammatory bowel
`disease, radiation-induced lung damage, sepsis and psoriasis.
`However, clinical use of IL-11 has been restricted due to
`reports of serious adverse events including edema. Moreover,
`IL-11 has been shown to have deleterious effects in various
`conditions.
`0006 For example, IL-11 has been found to act as an
`inhibitor of bone formation, and is critical for osteoclast
`formation and activity and bone resorption. Thus, blocking
`the activity of IL-11 has been proposed as a treatment for
`osteoporosis and for preventing bone resorption/promoting
`bone formation in other conditions such as metastatic bone
`cancer, myeloma, Paget’s disease of bone, and bone fracture
`and healing.
`0007 IL-11 signaling has been implicated as having a
`pathogenic role during the early phase of tuberculosis. Block
`ing IL-11 with an anti-IL-11 antibody was shown to diminish
`histopathology and neutrophilic infiltration of the lung tissue
`in mice infected with Mycobacterium tuberculosis.
`
`0008 Antagonism of IL-11 has also been proposed as a
`method of treating Th2-mediated disorders including asthma,
`chronic obstructive pulmonary disease (COPD), rhinitis,
`allergies and atopic dermatitis. In this regard, blocking IL-11
`signaling using a mutant form of IL-11 that does not induce
`signal transduction was shown to be of therapeutic benefit in
`a mouse model of asthma.
`0009 IL-11 and/or IL-11 RC. is overexpressed in liver can
`cer, pancreatic cancer, gastric cancer, osteosarcoma, endome
`trial cancer and ovarian cancer. Moreover, as discussed
`above, IL-11 induced gp130 dimerization leads to activation
`of STAT3, which induces expression of genes associated with
`angiogenesis (e.g. VEGF), cell cycle progression (e.g. cylin
`D1) and cell survival (e.g. Bcl-XL, survival). Persistent
`STAT3 activity appears to be associated with hematologic
`malignancies and tumors of epithelial origin. Excessive
`STAT3 activation promotes the growth and survival of gastric
`cells, is associated with increased gastric angiogenesis and
`leads to gastric tumorigenesis in mice. However, gastric
`inflammation, hyperplasia and tumor formation are Sup
`pressed in IL-11 unresponsive mice or in mice treated with a
`non-signaling mutant of IL-11.
`0010 IL-11 is also involved in other biological processes,
`Such as, inhibition of adipogenesis, induction of cachexia
`(e.g., cancer cachexia), induction of a febrile response, modu
`lation of extracellular matrix metabolism, stimulation of
`acute-phase reactants and embryo implantation.
`0011. It will be apparent to the skilled artisan from the
`foregoing that reagents that neutralize IL-11 signaling are
`desirable for their potential to provide a therapeutic benefit in
`any of a number of diverse conditions. Reagents that bind to
`the IL-11 RC. are also desirable since they have the advantage
`of being capable of specifically targeting cells in vivo as
`opposed to needing to bind to and neutralize soluble IL-11
`throughout a subject.
`0012 Despite this desirability, many reagents (e.g., anti
`bodies) that bind to IL-11 RC. do not neutralize IL-11 signal
`ing. For example, Blanc et al (Journal of Immunological
`Methods 241: 43-59, 2000) described a panel of 14 mouse
`monoclonal antibodies raised against human IL-11 RC, but
`none of them were capable of inhibiting IL-11-induced pro
`liferation of BaF3/gp130/IL-11R cells, indicating that the
`antibodies do not neutralize IL-11 signaling. Commercially
`available anti-IL-11 RC. antibodies, e.g., 4D12 available from
`Santa Cruz, Biotechnology, Inc., also do not neutralize IL-11
`signaling.
`
`SUMMARY
`0013. In producing the present invention, the inventors
`sought to produce reagents (e.g., antibodies and proteins
`comprising antigen binding domains thereof) that bind to
`IL-11 RC. and neutralize IL-11 signaling. The inventors pro
`duced a series of antibodies having Such activity, some of
`which potently neutralize IL-11 signaling, e.g., prevent pro
`liferation of IL-11-dependent BaF3 cell proliferation. These
`antibodies were shown to be cross-reactive with human
`IL-11RC. (hIL-11RC.) and cynomolgus monkey IL-11 RC. (cy
`noIL-11 RO), meaning that they may be used in primate mod
`els of human disease. The antibodies were also found to bind
`to overlapping epitopes. The inventors then affinity matured
`one of these antibodies and produced a series of additional
`antibodies having additional desirable properties, e.g., neu
`tralization of IL-11 signaling and/or improved affinity and/or
`
`Lassen - Exhibit 1008, p. 10
`
`

`

`US 2014/02199 19 A1
`
`Aug. 7, 2014
`
`sequences similar to human germline (e.g., having a reduced
`likelihood of inducing an immune response when adminis
`tered to a human).
`0014 Based on the foregoing, it will be apparent to the
`skilled artisan that the inventors have produced a protein
`comprising an antigen binding domain of an antibody, the
`antigen binding domain capable of binding to or specifically
`binding to IL-11RC. and neutralizing IL-11 signaling.
`0015. In one example, the present disclosure provides an
`IL-11RC.-binding protein comprising an antigen binding
`domain of an antibody, the antigenbinding domain binds to or
`specifically binds to IL-11 RC. and neutralizes IL-11 signal
`ing, wherein the antigenbinding domain is capable of binding
`to hiL-11RC. and cynoIL-11 RC.
`0016. In one example, the IL-11 RC-binding protein neu
`tralizes human IL-11 (hIL-11) and/or cynomolgus monkey
`IL-11 (cynoL-11) signaling.
`0017. The present disclosure additionally or alternatively
`provides an IL-11 RC.-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and the protein inhibits IL-11 (e.g.,
`hIL-11 or cynolL-11)-mediated proliferation of BaF3 cells
`expressing IL-11 RC. and gp130 with an ICso of 10 ug/ml or
`less. In one example, the ICso is 5ug/ml or less. For example,
`the ICs is 4 g/ml or less or 3.5 g/ml or less. In one example,
`the ICso is 3 ug/ml or less or 2 ug/ml or less. For example, the
`ICs is 1 g/ml or less. For example, the ICs is 0.9 g/ml or
`less or 0.8 g/ml or less or 0.7 g/ml. In one example, the ICso
`is 0.7 ug/ml or less. In one example, relating to each of the
`foregoing examples, the ICso can be 10 pg/ml or more or 10
`ng/ml or more.
`0018. In one example, the IL-11 RC-binding protein inhib
`its IL-11 (e.g., hIL-11 or cynolL-11)-mediated proliferation
`of BaF3 cells expressing IL-11 RC. and gp130 with an ICso at
`least about 1.5 fold greater than antibody 8E2 (comprising a
`heavy chain comprising a sequence set forth in SEQID NO:
`83 and a light chain comprising a sequence set forth in SEQ
`ID NO: 84). In one example, the ICs is at least about 2 fold
`greater or at least about 2.5 fold greater or at least about 3 fold
`greater than antibody 8E2.
`0019. In one example, the ICso is determined by culturing
`BaF3 cells expressing IL-11RC. and gp130(e.g., genetically
`modified to express IL-11 RC. and/or gp130) (e.g., about
`1x10" cells) in the presence of from about 0.5 ng/mL hIL-11
`to about 5 ng/mL hIL-11 (e.g., in the presence of about 0.5
`ng/mL hIL-11 or about 5 ng/mL hIL-11) for about 48 hours.
`In one example, proliferation is determined by measuring
`incorporation of 3H-thymidine into DNA during the last 6
`hours of culture. In assays performed to determine neutral
`ization of cynolL-11, the cells can be cultured in the presence
`offrom about 0.5 ng/mL cynoIL-11 to about 5 ng/mL cynoL
`11 (e.g., in the presence of about 0.5 ng/mL cynoL-11 or
`about 5 ng/mL cynoIL-11).
`0020. The present disclosure additionally or alternatively
`provides an IL-11 RC.-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and the level of binding of the
`IL-11RC.-binding protein to a polypeptide of SEQID NO: 86
`is lower than the level of binding of the IL-11 RC-binding to a
`polypeptide of SEQID NO:3 and/or 85.
`0021. The present disclosure additionally or alternatively
`provides an IL-11 RC.-binding protein comprising an antigen
`
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and the level of binding of the
`IL-11RC.-binding protein to a polypeptide of SEQID NO: 89
`is lower than the level of binding of the IL-11 RC-binding to a
`polypeptide of SEQID NO:3 and/or 85.
`0022. In one example, the level of binding is determined
`by Western Blotting and/or by fluorescence-activated cell
`sorting (FACS) of cells expressing the polypeptide.
`0023. In one example, the level of binding of the IL-11 RC.-
`binding protein to the polypeptide of SEQID NO: 86 or 89 is
`reduced by at least about 10 fold or 20 fold or 50 fold or 100
`fold or 150 fold or 200 fold compared to the binding of the
`IL-11RC.-binding protein to the polypeptide of SEQID NO:
`3 and/or 85.
`0024. In one example, the IL-11RC.-binding protein does
`not detectably bind to the polypeptide of SEQID NO: 86 or
`89.
`0025. In one example, the IL-11RC.-binding protein binds
`to a polypeptide of SEQID NO: 87 or 88. For example, the
`level of binding of the IL-11 RC.-binding protein binds to a
`polypeptide of SEQID NO: 87 or 88 is similar to or about the
`same as (e.g., within about 20% or 15% or 10% or 5%) of the
`level of binding to the polypeptide of SEQID NO: 3 and/or
`85.
`0026. The present disclosure additionally or alternatively
`provides an IL-11 RC-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC, and neu
`tralizes IL-11 signaling and the antigenbinding domain binds
`to an epitope comprising residues within the first fibronectin
`III domain of IL-11 RC.
`0027. In one example, the epitope comprises residues
`within the immunoglobulin-like domain and the first
`fibronectin III domain of IL-11RC.
`0028. In one example, the epitope comprises residues
`between amino acids 111-215 of SEQID NO: 1.
`0029. In one example, the epitope comprises residues
`between amino acids 1-215 of SEQID NO: 1.
`0030 The present disclosure additionally or alternatively
`provides an IL-11 RC-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and wherein the protein competi
`tively inhibits binding of antibody 8E2 (comprising a V
`comprising a sequence set forth in SEQID NO:37 and a V,
`comprising a sequence set forth in SEQ ID NO: 5) to hiL
`11RC. and/or to a polypeptide of SEQID NO:3 and/or 85.
`0031. The present disclosure additionally or alternatively
`provides an IL-11 RC-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and wherein the protein competi
`tively inhibits binding of antibody 8E4 (comprising a V
`comprising a sequence set forth in SEQID NO: 74 and a V,
`comprising a sequence set forth in SEQID NO: 73) to hiL
`11RC. and/or to a polypeptide of SEQID NO:3 and/or 85.
`0032. The present disclosure additionally or alternatively
`provides an IL-11 RC-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and wherein the protein competi
`tively inhibits binding of antibody 8D10 (comprising a V
`comprising a sequence set forth in SEQID NO: 76 and a V,
`
`Lassen - Exhibit 1008, p. 11
`
`

`

`US 2014/02199 19 A1
`
`Aug. 7, 2014
`
`comprising a sequence set forth in SEQID NO: 75) to hIL
`11 RC. and/or to a polypeptide of SEQID NO:3 and/or 85.
`0033. The present disclosure additionally or alternatively
`provides an IL-11 RC.-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and wherein the protein competi
`tively inhibits binding of antibody 8E2 (comprising a heavy
`chain comprising a V comprising a sequence set forth in
`SEQID NO:37 and a human IgG4 constant region and a light
`chain comprising a V, comprising a sequence set forth in
`SEQ ID NO: 5 and a human light chain constant region) to
`hIL-11 RC. and/or to a polypeptide of SEQID NO: 3 and/or
`85.
`0034. The present disclosure additionally or alternatively
`provides an IL-11 RC.-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and wherein the protein competi
`tively inhibits binding of antibody 8E4 (comprising a heavy
`chain comprising a V comprising a sequence set forth in
`SEQID NO: 74 and a human IgG4 constant region and a light
`chain comprising a V comprising a sequence set forth in
`SEQID NO: 73 and a human light chain constant region) to
`hIL-11 RC. and/or to a polypeptide of SEQID NO: 3 and/or
`85.
`0035. The present disclosure additionally or alternatively
`provides an IL-11 RC.-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and wherein the protein competi
`tively inhibits binding of antibody 8D10 (comprising a heavy
`chain comprising a V comprising a sequence set forth in
`SEQID NO: 76 and a human IgG4 constant region and a light
`chain comprising a V comprising a sequence set forth in
`SEQID NO: 75 and a human light chain constant region) to
`hIL-11 RC. and/or to a polypeptide of SEQID NO: 3 and/or
`85.
`0036. The present disclosure additionally or alternatively
`provides an IL-11 RC.-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and wherein the protein competi
`tively inhibits binding of antibody 8E2 (comprising a heavy
`chain comprising a sequence set forth in SEQID NO: 83 and
`a light chain comprising a sequence set forth in SEQID NO:
`84) to hiL-11RC. and/or to a polypeptide of SEQ ID NO: 3
`and/or 85.
`0037. The present disclosure additionally or alternatively
`provides an IL-11 RC.-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and wherein the protein competi
`tively inhibits binding of antibody 8E4 (comprising a heavy
`chain comprising a sequence set forth in SEQID NO: 92 and
`a light chain comprising a sequence set forth in SEQID NO:
`91) to hiL-11RC. and/or to a polypeptide of SEQ ID NO: 3
`and/or 85.
`0038. The present disclosure additionally or alternatively
`provides an IL-11 RC.-binding protein comprising an antigen
`binding domain of an antibody, wherein the antigen binding
`domain binds to or specifically binds to IL-11 RC. and neu
`tralizes IL-11 signaling and wherein the protein competi
`tively inhibits binding of antibody 8D10 (comprising a
`
`heavy chain comprising a sequence set forth in SEQID NO:
`94 and a light chain comprising a sequence set forth in SEQ
`ID NO: 93) to hiL-11RC. and/or to a polypeptide of SEQID
`NO:3 and/or 85.
`0039. The present disclosure additionally or alternatively
`provides an IL-11 RC-binding protein comprisin

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket